Amicus Therapeutics, Inc.
3675 Market Street
Philadelphia
Pennsylvania
19104
United States
Website: http://www.amicusrx.com/
Email: info@amicusrx.com
About Amicus Therapeutics, Inc.
393 articles with Amicus Therapeutics, Inc.
-
Amicus Therapeutics Reports Preliminary 2022 Revenue and Provides 2023 Strategic Outlook
1/9/2023
Amicus Therapeutics today provided its preliminary and unaudited 2022 revenue, corporate updates, and full-year 2023 outlook.
-
Amicus Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
1/3/2023
Amicus Therapeutics announced that Bradley Campbell, President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 9, 2023 at 2:15 p.m. PT.
-
Amicus Therapeutics Receives Positive CHMP Opinion for Pombiliti™ (cipaglucosidase alfa) for Late-Onset Pompe Disease
12/16/2022
Amicus Therapeutics (Nasdaq: FOLD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending marketing authorization of cipaglucosidase alfa, a long-term enzyme replacement therapy (ERT) used in combination with miglustat for adults with late-onset Pompe disease (LOPD).
-
Amicus Therapeutics to Present at the Stifel 2022 Healthcare Conference
11/15/2022
Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Stifel 2022 Healthcare Conference in New York, NY on Wednesday, November 16, 2022 at 9:45 a.m. E.T.
-
Amicus Therapeutics Provides EU Regulatory Update for AT-GAA
11/7/2022
Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today provided an EU regulatory update for AT-GAA.
-
Amicus Therapeutics Announces Third Quarter 2022 Financial Results and Corporate Updates
11/7/2022
Amicus Therapeutics today announced financial results for the quarter ended September 30, 2022.
-
U.S. FDA Defers Action on Filing for AT-GAA in Late-onset Pompe Disease
10/28/2022
Amicus Therapeutics (Nasdaq: FOLD) today announced that the U.S. Food and Drug Administration (FDA) has deferred action on the Biologics License Application (BLA) for cipaglucosidase alfa, the biologic component of AT-GAA.
-
Amicus Therapeutics to Announce Third Quarter 2022 Financial Results on November 7, 2022
10/27/2022
Amicus Therapeutics announced that the Company will host a conference call and live audio webcast on Monday, November 7, 2022 at 8:30 a.m. ET to discuss financial results for the third quarter ended September 30, 2022.
-
Amicus Therapeutics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
9/8/2022
Amicus Therapeutics announced that management will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference in New York, NY on Wednesday, September 14, 2022 at 12:20 p.m. E.T.
-
This week holds moments of truth for Provention's type 1 diabetes drug and bluebird bio's gene therapy for beta-thalassemia. Amicus and Incyte are coming up at the end of the month.
-
Amicus Therapeutics to Announce Second Quarter 2022 Financial Results on August 4, 2022
7/26/2022
Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, August 4, 2022 at 8:30 a.m. ET to discuss financial results for the second quarter ended June 30, 2022.
-
As the calendar pages continue to turn, the FDA has a slew of novel drugs awaiting approval, several of which are likely to become game-changers for patients and key assets for companies.
-
Amicus Therapeutics to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
6/8/2022
Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference in Rancho Palos Verdes, CA on Wednesday, June 15, 2022 at 11:20 a.m. P.T.
-
The revised PDUFA action date for miglustat is August 29, 2022, while the new date for cipaglucosidase alfa is October 29, 2022. Amicus expects the agency to approve the applications together.
-
Amicus Therapeutics Receives Notification of PDUFA Date Extensions for AT-GAA
5/10/2022
Amicus Therapeutics announced that the U.S. Food and Drug Administration has extended the review period by 90 days for the Biologics License Application for cipaglucosidase alfa and the New Drug Application for miglustat, the two components of AT-GAA.
-
CORRECTING AND REPLACING -- Amicus Therapeutics Announces First Quarter 2022 Financial Results
5/9/2022
Amicus Therapeutics, a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, announced financial results for the quarter ended March 31, 2022.
-
Amicus Therapeutics Announces First Quarter 2022 Financial Results
5/9/2022
Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced financial results for the quarter ended March 31, 2022.
-
Amicus Therapeutics to Present at the Bank of America 2022 Healthcare Conference
5/4/2022
Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Bank of America 2022 Healthcare Conference in Las Vegas, NV on Wednesday, May 11, 2022 at 12:00 p.m. P.T.
-
Amicus Therapeutics to Announce First Quarter 2022 Financial Results on May 9, 2022
4/26/2022
Amicus Therapeutics announced that the Company will host a conference call and live audio webcast on Monday, May 9, 2022 at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2022.
-
Amicus Announces Issuance of New U.S. Composition of Matter Patent for Galafold® (migalastat), Strengthening Patent Protection Through 2038
4/19/2022
Amicus Therapeutics announced that the United States Patent and Trademark Office has issued U.S. Patent No. 11,304,940, which is directed to a composition of matter covering migalastat.